We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Optimal Rule-Out Biomarker Strategy Developed for Acute MI

By LabMedica International staff writers
Posted on 27 Sep 2016
Assessment of patients presenting to the Emergency Department (ED) with symptoms suggestive of acute coronary syndrome (ACS) represents a major clinical challenge, since the majority of patients do not have a final diagnosis of acute myocardial infarction (AMI).

A multi-marker strategy, combining high-sensitivity troponins (hs-cTn) with an early cardiac marker may improve sensitivity and increase the proportion of low-risk patients suitable for early discharge by allowing a higher troponin threshold to be utilized. Heart Fatty Acid Binding Protein (H-FABP), a highly myocardium-specific protein and early rise marker of ACS, is a potential candidate.

Scientists at the University of Otago (Dunedin, New Zealand) and their medical colleagues enrolled consecutive patients presenting acutely to the emergency department (ED) with symptoms suggestive of AMI. Patient assessment included blood sampling for contemporary TnI (c-TnI) at presentation and six to 12 hours later. The primary end point was AMI during initial hospital attendance. AMI diagnosis was based on evidence of myocardial necrosis, together with clinical features consistent with myocardial ischemia (ischemic symptoms, ECG changes or imaging evidence).

Necrosis was diagnosed on the basis of a rising or falling pattern of the routine laboratory c-TnI (ARCHITECT c-TnI assay, Abbott Diagnostics, Lake Forest, IL, USA), with at least one value above 0.028 ng/mL. Hs-cTnI concentrations were measured on the ARCHITECT STAT platform. Hs-cTnT concentrations were measured with the Roche Elecsys hs-cTnT assay. H-FABP concentrations were measured with an immunoturbidimetric H-FABP assay on the ARCHITECT platform.

The team recruited 1,079 patients including 248 with AMI. H-FABP of less than 4.3ng/mL plus hs-cTnI of greater than 10.0 ng/L together with a negative ECG maintained more than 99% sensitivity for AMI whilst classifying 40.9% of patients as low-risk. The combination of H-FABP less than 3.9ng/mL and hs-cTnT of greater than 7.6ng/L with a negative ECG maintained the same sensitivity whilst classifying 32.1% of patients as low risk.

The authors concluded that in patients requiring rule-out of AMI, the addition of H-FABP to hs-cTn at presentation in the absence of new ischemic ECG findings may accelerate clinical diagnostic decision making by identifying up to 40% of such patients as low-risk for AMI on the basis of blood tests performed on presentation. If implemented this has the potential to significantly accelerate triaging of patients for early discharge from the ED. The study was published on August 31, 2016, in the journal BMC Emergency Medicine.

Related Links:
University of Otago
Abbott Diagnostics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.